Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in rapidly progressive ADPKD
NCT04705051Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of venglustat in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Sanofi. Primary endpoint: Total Kidney Volume at 24 months. Started Feb 2021; status: terminated.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04705051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705051.